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Abstract
The reservoir for Neisseria meningitidis (Nm) is the human oropharynx. Implementation of
Nm serogroup C (NmC) glycoconjugate vaccines directly reduced NmC carriage. Prophy-
lactic vaccines are now available to prevent disease caused by the five major Nm disease
causing serogroups (ABCWY). Nm serogroup B (NmB) vaccines are composed of antigens
that are conserved across Nm serogroups and therefore have the potential to impact all Nm
carriage. To assess the effect of these vaccines on carriage, standardized approaches to
identify and group Nm are required. Real-time PCR (rt-PCR) capsule grouping assays that
were internally controlled to confirm Nm species were developed for eight serogroups asso-
ciated with carriage (A, B, C, E, W, X, Y and Z). The grouping scheme was validated using
diverse bacterial species associated with carriage and then used to evaluate a collection of
diverse Nm carriage isolates (n=234). A scheme that also included porA and ctrA probes
was able to speciate the isolates, while ctrA also provided insights on the integrity of the
polysaccharide loci. Isolates were typed for the Nm vaccine antigen factor H binding protein
(fHbp), and were found to represent the known diversity of this antigen. The porA rt-PCR
yielded positive results with all 234 of the Nm carriage isolates. Genogrouping assays clas-
sified 76.5% (179/234) of these isolates to a group, categorized 53 as nongenogroupable
(NGG) and two as mixed results. Thirty seven NGG isolates evidenced a disrupted capsular
polysaccharide operon judged by a ctrA negative result. Only 28.6% (67/234) of the isolates
were serogrouped by slide agglutination (SASG), highlighting the reduced capability of car-
riage strains to express capsular polysaccharide. These rt-PCR assays provide a compre-
hensive means to identify and genogroup N.meningitidis in carriage studies used to guide
vaccination strategies and to assess the impact of novel fHbp containing vaccines on
meningococcal carriage.
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Introduction
Meningococcal infection is a major cause of bacterial meningitis and septicemia worldwide.
Neisseria meningitidis (Nm) commonly colonizes the oropharyngeal mucosa without causing
any detectable symptoms [1]. Most individuals will, at one time or another during their lives,
carry the bacterium asymptomatically in their throats (a condition defined as carriage). Inva-
sive disease is rare in non-epidemic areas such as Europe and the US, occurring at a rate of 0.5–
10 cases per 100,000 population per year [2]. However, before the implementation of serogroup
A glycoconjugate vaccines, rates of up to 1,000 cases per 100,000 population per year had been
recorded in the epidemic region of sub-Saharan Africa [3–6].
Nm produces a polysaccharide capsule that is exhibited on the cell surface of invasive isolates
and helps protect the bacterium from the human immune system [7]. Nm can be classified into
serogroups based on the structure of its polysaccharide capsule and the use of polysaccharide-
specific antisera. Twelve serogroups have been described (A, B, C, E, H, I, K, L, W, X, Y and Z),
but only five (A, B, C, W and Y) are responsible for greater than 90% of the invasive disease
worldwide. Several prophylactic capsular polysaccharide and polysaccharide-conjugate based
vaccines against serogroups A, C, Y, andW have been developed and licensed [8], however sim-
ilar approaches to develop a N.meningitidis serogroup B (NmB) vaccine have failed. The ser-
ogroup B capsular polysaccharide is composed of polysialic acid repeating units that are similar
to structures found on human neuronal cells (particularly during fetal development) and are
not suitable as vaccine antigens [9]. One alternate strategy to prevent NmB disease focused on
vaccines produced from bacterial outer membrane vesicles (OMVs). However, due to consider-
able sequence heterogeneity of the immunodominant PorA vesicle antigen, OMV vaccines are
not suitable in endemic situations where broader protective efficacy is required [10]. Several
non-capsular NmB proteins have been considered as antigens for a broadly effective vaccine
and the surface lipoprotein factor H binding protein (fHbp) has emerged as a leading candidate.
Molecular epidemiology of NmB clinical isolates demonstrated that fhbp gene sequences segre-
gate into two subfamilies, designated A and B [11]. Protein variants within subfamilies share
>83% amino acid identity, but only 60%–75% pairwise identity between subfamilies [12]. Con-
sistent with the sequence diversity between subfamily A and B, the breadth of bactericidal activ-
ity following immunization with lipidated fHbp antigens is subfamily restricted [11,13]. Two
vaccines, each containing fHbp, have been licensed in the United States for the prevention of
invasive meningococcal disease caused by NmB. The first, bivalent rLP2086 (Trumenba), is
composed of two lipidated fHbp variants (A05, B01), one each from subfamily A and B to con-
fer breadth of immune coverage. 4CMenB (Bexsero), a four component NmB vaccine that
includes a non-lipidated fHbp variant from subfamily B (B24) together with two additional
meningococcal proteins and OMV, has more recently been licensed in the US.
Eight meningococcal serogroups (A, B, C, E, W, X, Y and Z) are commonly detected in car-
riage isolates [14]. The epidemiology of meningococcal carriage and disease is the subject of
ongoing studies, particularly as prophylactic vaccines have now been developed for each of the
five serogroups associated with disease [15]. Implementation of the N.meningitidis serogroup
C (NmC) glycoconjugate vaccine in the UK reduced not only the disease caused by this ser-
ogroup, but also its carriage rate [16] resulting in herd immunity being extended to non-vacci-
nated age groups [17]. The introduction of meningococcal vaccines against NmB that are
based on protein antigens, such as factor H binding protein (fHbp), may also impact other Nm
serogroups [18,19]. The development of standardized rapid and robust approaches to assess
the impact of these vaccines on meningococcal carriage is desirable. Preliminary studies con-
ducted with Bexsero, have demonstrated that although the vaccine failed its primary endpoint
for the reduction of carriage, it may have an effect on carriage strain acquisition over time.
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Overall, an 18% reduction in carriage was reported for all isolates [15]. In this study, carriage
isolates were grouped using a combination of serogrouping and genogrouping approaches to
characterize the disease associated serogroups (ABCWY). In contrast to invasive strains, many
meningococcal isolates obtained from asymptomatic carriers lack capsule expression and are
therefore ungroupable by serology [20,21]. For that reason, a comprehensive strategy aimed at
characterizing carriage isolates must include molecular in addition to serological methods.
Polymerase chain reaction (PCR) is a fast and sensitive method that has been used both in clin-
ical diagnostics and in the management of infectious diseases since the mid-1990s. It is the pre-
ferred non-culture method for identifying the causal agent of meningitis in the clinic,
especially since the early administration of antibiotics often prevents the recovery of viable bac-
teria [22,23]. In contrast to conventional gel-based PCR assays, real-time PCR (rt-PCR) pro-
vides higher sensitivity, speed, throughput and prospective automation, all desirable features
for epidemiological studies. In addition, closed-tube analysis eliminates the risk of potential
contamination during post-PCR handling steps.
Reliable detection methods should also include assay controls that confirm the presence of
Nm in the assay. Assays for a variety of Nm specific loci have been described in the literature.
These include insertion elements, 16S ribosomal RNA, the capsule regulatory gene crgA, the
capsule transport gene ctrA, porA, and sodC [22,24–29]. The gene encoding CtrA is the most
widely used target for meningococcal identification in invasive disease. However, there are few
studies to demonstrate that this is an appropriate approach for carriage isolates which may
have incomplete or absent capsular polysaccharide operons [30]. Jordens and Heckels reported
the development of a porA rt-PCR assay that identified several isolates that were missed by
using only ctrA [28]. To increase accuracy and prevent false negative results, Whiley and col-
laborators used a duplex rt-PCR approach that targeted both porA and ctrA [31]. Although this
is successful at detecting most Nm invasive strains, some may still be missed due to sequence
polymorphisms [32,33]. The reported sodC assay [29] was effective at identifying 99.7% (624/
626) of invasive and carriage Nm strains, and was superior to the ctrA assay (71.6%, 448/626).
The 28.4% (178/626) of isolates that were not identified as Nm using the ctrA assay was com-
prised entirely of nongroupable (NG) strains.
PCR grouping of meningococci relies on the accurate detection of the gene(s) responsible for
determining the capsular type. The enzymes that synthesize and translocate capsular polysac-
charides are encoded by an operon that is composed of between seven and eleven genes flanked
by tex and galE (Fig 1) [34,35]. Thus, rt-PCR assays for genotypic grouping of Nm based on the
detection of serogroup-specific genes csaB (NmA), csb (NmB), csc (NmC), csw (NmW), csxB
(NmX) and csy (NmY) have been described [36,37]. However, no rt-PCR assays for genogroup-
ing NmE and NmZ have been reported [29,37,38]. We therefore sought to develop assays to
identify and genogroup carriage isolates, while trying to address the shortcomings present in
current assay designs. We developed optimized porA and ctrA rt-PCR assays that identified Nm
and assays that grouped isolates from the eight major serogroups (A, B, C, E, W, X, Y and Z) to
assist in surveying the current state of meningococcal carriage. Carriage isolates were also typed
for fHbp to evaluate its distribution across the Nm carriage isolates.
Methods
Bacterial Strains
Three panels of bacterial isolates were employed to develop and evaluate the assays described
herein. The first panel consisted of NmE (n = 69) and NmZ (n = 13) strains and was used to
obtain the DNA sequences of capsule biosynthesis and transport genes. The second panel was
used for proficiency to confirm the specificity of the PCR assays and was composed of: NmA
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(n = 4), NmB (n = 5), NmC (n = 3), NmE (n = 69), NmW (n = 3), NmX (n = 3), NmY (n = 5),
NmZ (n = 9), Nm cnl (n = 6), and 38 additional strains that included other human pathogens
and commensal organisms, specifically: N. cinerea (n = 1), N. gonorrhoeae (n = 2), N. lactamica
(n = 2), N. sicca (n = 2) and N. subflava (n = 2); Haemophilus influenzae [type a (n = 1), b
(n = 2), c (n = 2), d (n = 1), e (n = 1), f (n = 1), i (n = 1), non-typeable (n = 2), biogroup aegyptius
(n = 1)],H. haemolyticus (n = 1) and H. parainfluenzae (n = 2); Streptococcus pyogenes (n = 1),
S. agalactiae (n = 2), S. pneumoniae type 1, 5, 14 and 19F (one of each; n = 4); Staphylococcus
aureus (n = 2) andMoraxella catarrhalis (n = 5). These strains were obtained either from
ATCC (Bethesda, MA) or from Pfizer’s collection of clinical isolates.
The third panel was composed of Neisseria carriage isolates (n = 234) that were selected in a
non-biased manner from strains collected over the course of two studies that investigated
Fig 1. Location of serogroup-specific PCR amplicons in capsular biosynthesis genes of N.meningitidis serogroups A, B, C, W, Y, E, Z, and X.
Genes ctrA-D encode capsule transport proteins conserved among all eight serogroups. Genes cssA-C are responsible for the sialic acid capsular
component of serogroups B, C, W, and Y, while csb-c-w-y encode the sialyltransferases that produce the serogroup-specific linkages of sialic acid with
glucose or galactose. Capsule biosynthesis genes csaA-D, csxA-C, cseA-G, and cszA-D, are unique to A, X, E, and Z serogroups, respectively.
Polysaccharide transport and biosynthesis genes are flanked by tex and galE (black arrows). Genes at the distal end of the biosynthetic clusters in
serogroups B, C, W, and Y are shown as dotted arrows, and annotated as described previously [35]. The green arrows indicate the location of the ctrA
primers used to detect all eight serogroups. Light blue arrows represent the initial primers designed to identify NmE and NmZ, based on sequence at the 5’
end of the ctrA gene. The red arrows represent the position of the final primers designed for the eight serogroup-specific assays. The blow-up at the bottom
illustrates the position of ctrA primers and probes in greater detail.
doi:10.1371/journal.pone.0132140.g001
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meningococcal carriage in the UK during 1997–2001 (n = 2296). The first study was conducted
at the University of Nottingham [39] and the second was carried out in a multicenter survey of
carriage during the introduction of a NmC conjugate vaccine and on two successive years [16].
These isolates were previously grouped [16,39] using a standard PCR assay.
Neisseria strains were grown overnight on chocolate agar plates at 37°C under 5% CO2 and
cell lysates were generated by heating a loopful of colonies suspended in 100 μL H2O for 5 min
at 95°C. Lysates were centrifuged at 14,000 × g for 5 min and an aliquot was diluted 20- to
50-fold in TE buffer pH 8.0 (10 mM Tris-HCl pH 8.0, 1 mM EDTA) for testing.
Genomic DNA Extraction
Bacteria from an overnight chocolate agar culture were collected in 3 mL sterile PBS. A 500 μL
aliquot of this suspension was lysed and processed using the DNeasy Blood and Tissue kit
(Qiagen, Valencia, CA) as recommended by the manufacturer. DNA was eluted in 200 μL of
Buffer EB and its concentration determined by measuring A260 using a Nanodrop ND-1000
spectrophotometer (Nanodrop Tech, Wilmington, DE). DNA integrity was evaluated by run-
ning 500 ng in a 1% agarose gel. DNA standards were prepared by making six 10-fold serial
dilutions ranging from 20 to 2×106 genome copies per microliter and were used to determine
efficiency and the lower limit of quantitation for each rt-PCR assay.
Alignments and Primer-Probe Design
Real-time PCR primers and probes were designed using DNASTAR Lasergene 10 and Primer
Express V 3.0. (Life Technologies, Grand Island, NY) and are listed in Table 1. Conserved and
discriminating regions within target genes were identified based on nucleotide sequence align-
ments of N.meningitidis sequences retrieved from GenBank or from Pfizer’s collection of clini-
cal isolates. For meningococcal identification, primer-probe sets were targeted to conserved
regions of genes encoding 16S rRNA, crgA, porA and ctrA. We designed primer-probe sets for
each of these four genes and evaluated them with serial dilutions of NmC and NmY genomic
DNA to calculate PCR efficiency and sensitivity. Genogrouping PCR primers and probes devel-
oped by other investigators [36] were first evaluated in silico. Then, alignments of GenBank
sequences for csaB (NmA), csb (NmB), csc (NmC), csw (NmW), csy (NmY), and csxB (NmX)
were used to design Taqman Minor Groove Binder (MGB) probes for genogrouping N.menin-
gitidis A, B, C, W, X, Y and Taqman probes for serogroups E and Z (Table 1). Initial NmE and
NmZ primers and probes were selected to target the 5’end of the ctrA gene, which harbours
nucleotide sequences capable of discriminating serogroups E, X, and Z [40]. Alignments of
NmE and NmZ ctrA sequences extracted from GenBank (AF520907 and AF520909, respec-
tively) together with ctrA sequences generated in house from 64 NmE and 12 NmZ isolates,
guided the design of group E and Z specific primers and probes. Later, an improved set of
primers and probes targeting capsule biosynthesis genes cszA (NmZ) and cseG (NmE) were
designed based on alignments of cszA sequences from eight NmZ isolates (described in the
next section) to Genbank sequence AJ744766 (NmZ) and cseG sequences from 64 NmE isolates
to Genbank sequence AJ576117 (NmE), respectively.
To confirm specificity, all primer and probe sequences were used as queries in BLAST
searches against the GenBank nucleotide database. If one primer or probe displayed high
homology to other targets or species, the specificity relied on the second primer and probe in
the assay to diminish the risk of generating nonspecific results. Primers were manufactured by
Integrated DNA Technologies, Inc. (Coralville, IA). Probes labeled with FAM, VIC or NED
and non-fluorescent quenchers (NFQ) were manufactured by Life Technologies. Real-time
PCR assays were optimized using both genomic DNA and plasmids containing the target
Expanded Meningococcal Genogrouping Assay
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Table 1. Real-Time PCR Primers and Probes for Identification and GenogroupingN.meningitidis.
Serogroup Gene Name Sequence 5’!3’ Ct LODb
All Nm16S-F913 CGGTGGATGATGTGGATTAATTC
16S rRNA Nm16S-R986 CCGGAGGATTCCGTACATGT 34.40
Nm16S-P947 FAM-AAGAACCTTACCTGGTCTT-MGBNFQ
All NmcrgA-F484 AGCCGCTTCCGCGTAATC
crgA NmcrgA-R565 GGTGACCGGCAAGCTCTTC 32.8
NmcrgA-P505 FAM-AGTCCTGAATACCTGGC-MGBNFQ
All NmporA-F928 CGCTTCGGTAATGCAGTTCC
porA NmporA-R1055 CGTTTGGAAAAATCATAATCAACG 35.28
NmporA-Pr1009 FAM-TGGTATTTTCGCCTTTTTTACCGCGTT-BHQ-1
All NmctrA-F860 TGGGCGGTTTGCAAGATC
ctrA NmctrA-R947 TGACGTTCTGCCGGCAAT 33.81
NmctrA-Pr900 VIC-CACACCACGCGCATCA-MGBNFQ
A NmAsacB-F1150 GCCACAAAGTGCCCTTCCT
csaB NmAsacB-R1213 TGGTATATGGTGCAAGCTGGTT 35.48
NmAsacB-P1172 NED-TTTAGCTCACATGCTATTG-MGBNFQ
B NmBsiaD-F895 CCTCGGCTGGTAGTTATTAATGAAC
csb NmBsiaD-R980 GCCAGGCCTATAATTCCTTTAGGA 33.35
NmBsiaD-P922 FAM-CCTTTTCTAATTGAGCCCCTAA-MGBNFQ
C NmCsiaD-F496 GCACATTCAGGCGGGATTA
csc NmCsiaD-R564 TTGAGATATGCGGTATTTGTCTTGA 34.84
NmCsiaD-P517 NED-ACAAGCCAATCTATTGCT-MGBNFQ
X NmXxcbB-F364 TTGCGCCGCCATAAAGA
csxB NmXxcbB-R428 GAGGCAGATTTGCGTTTTGG n.a
NmXxcbB-P393 FAM-ACTGACACCACCTTC-MGBNFQ
W NmWsynG-F872 TGGTGTATGATATTCCAATCGTTGT
csw NmWsynG-R982 CCATTCCAGAAATATCACCAGTTTT 34.00
NmWsynG-P915 VIC-AGCGAATGATTACAGTAACT-MGBNFQ
Y NmYsynF-F954 GTACGATATCCCTATCCTTGCCTATAA
csy NmYsynF-R1060 CCATTCCAGAAATATCACCAGTTTTA 34.66
NmYsynF-P990 VIC-TGGAGCGAATGATTTTAGCAA-MGBNFQ
E NmE ctrA-F113 ACGGCATGTGGAGCCATT
ctrA NmE ctrA-R175 TTGCCCTAAGGAGACAATCTTTTT 33.17
NmE ctrA-P132 FAM-CTTCCTCAGGTCCAAGTG-MGBNFQ
Ea capEH-F738 AGATTTACGTCGTGCCTTCGA
cseG capEH-R865 CATGCATATAGGCTTCAGCTTCTG 30.75
capEH-P810 FAM-TCCTAAATATGTTTCTGCTGATGCCCGC-NFQ
Z NmZ ctrA-F60 TGGTTACGGCATGTAGTGCTATTC
ctrA NmZ ctrA-R129 TGTTGCCCTAAAGAGACAATTTTTT 33.49
NmZ ctrA-P85 FAM-CTCCTCCGGCCCTAG-MGBNFQ
Za capZA-F39 GCACTATGGTCATATTCGCCTTT
cszA capZA-R116 TCATCAGTTGAGATGGCAACAGT 30.84
capZA-P65 FAM-AACGTGCAAAAGCTCTAGGCGACCATC-NFQ
MGB = minor groove binder; NFQ = non-ﬂuorescent quencher; BHQ-1 = Black Hole Quencher 1. Probes were ﬂuorescently labeled with FAM, VIC or
NED.
a Higher speciﬁcity; located in group-speciﬁc capsule biosynthesis gene.
b Ct resulting when 100 genome copies tested (lowest standard), except for 16S, which is the result of 400 genome copies because Nm carries four
copies of 16S per genome.
doi:10.1371/journal.pone.0132140.t001
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region as templates. The testing of genomic DNA from meningococcal strains of serogroup A,
B, C, E, W, X, Y and Z determined that the assays were serogroup specific. All assays met the
acceptable PCR efficiency criteria of 90–110%. Their efficiency ranged from 92.3% to 103.1%
as calculated from standard curves resulting from testing 10-fold serial dilutions of template
(1x107 to 100 genome copies). Using data from the same standard curves we determined the
assay sensitivity to be at least 100 genome copies.
Cloning and Sequencing of the cps Biosynthesis Locus of NmZ and
cseG from NmE
Eight isolates from our collection (PMB397, PMB667, PMB1473, PMB1867, PMB358,
PMB828, PMB562 and PMB3083) identified as NmZ based on the sequence of their ctrA
gene, were chosen for PCR amplification of region A (~8.5 kb) of the capsule biosynthesis
locus (Fig 1). Five microliters of lysate were amplified for 30 PCR cycles with 200 nM of each
primer ctrAUR2 (5’-TTTGTCGCGGATTTGCAACTA-3’) and NmZgalE rev (5’-
CCGGTGCCGCCGGTAA-3’), 25 μL 2x TaKaRa ExTaq PCR master mix (Clontech Laborato-
ries, Inc., Mountain View, CA) in a 50-μL reaction. Each cycle included 10 s at 98°C, 30 s at
60°C and an 8 min extension step at 68°C. PCR products were gel purified using the MinElute
Gel Extraction Kit (Qiagen) and 5–50 ng was ligated into pSC-A using the StrataClone PCR
cloning kit (Stratagene, La Jolla, CA). The resulting plasmids were sequenced by Sanger
chemistry in an ABI 3730 (Life Technologies) using a series of forward and reverse primers
based on the GenBank reference sequence AJ744766. Contigs were assembled and analyzed
using Sequencher software 4.10.1 (Gene Codes, Ann Arbor, MI) to generate consensus
sequences from each isolate. These sequences have been deposited in GenBank under acces-
sion numbers (submission in progress). Further alignments and comparison to the reference
sequence were performed using DNASTAR Lasergene 10 (DNASTAR Inc., Madison, WI).
For NmE, we amplified and sequenced an 853bp fragment of cseG from 64 isolates as follows:
5 μL of lysate were amplified for 30 PCR cycles with 200 nM of each primer cpEgF15 (5’-
TCTAAAATTGGCGGTTGAAA-3’) and cpEgR907 (5’-CTTTATTGGACTCTTTTAC-
GACTA-3’), 25 μL 2x TaKaRa ExTaq PCR master mix in a 50-μL reaction. Each cycle
included 10 s at 98°C, 30 s at 50°C and a 1 min extension step at 68°C. Resulting PCR prod-
ucts were sequenced as described above for the NmZ plasmids.
Real-Time PCR Assay and Analysis
To evaluate the specificity of the primer-probe sets shown in Table 1, rt-PCR reactions were
performed on strains from the proficiency panel under the following conditions: 25-μL reac-
tions containing 400 nM of each primer, 200 nM of fluorescent probe, 12.5 μL of 2x Quanti-
Tect Probe Kit (Qiagen) and 5 μL of DNA or lysate were assembled in MicroAmp Optical
96-Well Reaction Plates (Life Technologies). Reactions were run in an ABI Real-Time PCR
System 7500 (Life Technologies) using these cycling parameters: 15 min at 95°C, followed by
40 cycles of 30 s at 95°C and 1 min at 60°C. The analysis performed by the 7500 System SDS
Software v1.3.1 generated the threshold cycle (Ct) for each reaction. The passing criteria for
primer-probe sets designed to identify Nm and each serogroup was to generate a Ct value
appropriate to the number of copies added to the reaction and no Ct values with DNA tem-
plate from other species. Primer-probe sets resulting in Ct values lower than 40 with any
strain other than Nm were deemed nonspecific and therefore rejected as meningococcal iden-
tification sets.
To evaluate the testing panel of carriage isolates, rt-PCR reactions were assembled using 400
nM of each primer and 200 nM of probe, 12.5 μL of QuantiFast Probe PCR mix (Qiagen) and
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5 μL of lysate in MicroAmp Optical 96-Well Reaction Plates. Reactions were performed under
fast cycling conditions: 3 min at 95°C followed by 40 cycles of 3 s at 95°C and 35 s at 60°C.
Each assay plate included negative control wells with no template and wells with ~1x104 copies
of a positive control plasmid carrying the target gene. Each of the eight genogrouping assays
was performed as singleplex reactions. All reactions resulting in a Ct greater than 35 were des-
ignated as negative, because this value is approaching the limit of detection (LOD) of the assay.
If the Ct value was lower than 30, the reaction was considered positive. Genogrouping reactions
with Ct values between 30 and 35 were compared to the Ct obtained for porA with the same
isolate and the difference between the two values was then calculated. If the Ct differential was
greater than six (indicative of a near 80-fold difference in DNA input), the reaction was consid-
ered negative. Conversely, if this Ct difference was smaller than six, the reaction was considered
positive. This algorithm was envisioned because all targets are present in one copy per genome
and therefore each individual Nm test isolate was expected to yield similar Ct values with porA,
ctrA, and the capsule grouping assay. The same algorithm was able to resolve reactions with
positive results for two or more genogroups (Multiple, Table 2).
Isolates with negative genogrouping results (nongenogroupable, NGG) were subject to PCR
to determine the capsule null locus (cnl) as described by Claus et al. [20].
SASG Assay
Serogrouping of the carriage isolate collection was accomplished by conducting slide agglutina-
tion with commercial antisera using published methods [16].
fHbp Analysis
Characterizaton of fHbp variants in the carriage isolates was performed by PCR amplification
and sequencing of fhbp as described in Murphy et al. [12]. fHbp variants segregate into two
subfamilies, designated A and B; fHbp variant A05 corresponds to variant 5 from subfamily A.
Table 2. Genogroup Distribution andMeningococcal Identification of the 234 Carriage Isolates by Real-Time PCR.
Serogroup SASG RT-PCR w/Algorithm RT-PCR:SASGAgreement porA ctrA fhbp porA:fhbp ratio (%)
B 41 77 40/41 77 72 77 100
C 3 20 3/3 20 20 20 100
E 2 21 2/2 21 21 21 100
W 12 28 11/12 28 28 28 100
X 3 2 1/3 2 2 2 100
Y 6 27 4/6 27 27 27 100
Z 4 4 4 4 100
Multiplea 2 2 2 2
Subtotal 67 181 61/67 (91%) 181 176 181 100
cnl n.a. 33 33 4 33
UKN n.a. 20 20 12 20
NG/NGG 167 53 50/53 53 16 53 100
Total 234 234 234 193 234 100
n.a. = not applicable; NG = nongroupable by SASG assay; NGG = nongenogroupable by rt-PCR assays; UKN = unknown (no result by genogrouping rt-
PCR assays and cnl PCR negative or not done).
aPositive result with two rt-PCR genogrouping assays (Ct<30).
doi:10.1371/journal.pone.0132140.t002
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Results
Real-time Universal PCR assays Specific for N.meningitidis
To develop rt-PCR assays for the unambiguous identification of Nm isolates, primer-probe
sets were designed to target 16S rRNA, crgA, porA, or ctrA genes. For each gene we chose the
primer-probe set displaying the highest efficiency and a sensitivity to detect as few as 100
genome copies. The specificity of the primer-probe sets was evaluated using a subset of 46 bac-
terial strains from the proficiency panel that included one NmC, one NmY, six Nm cnl, and the
38 additional non-meningococcal isolates (as detailed in Methods). Only the porA and ctrA
assays were 100% specific for Nm (S1 Table). Although N. subflava contains ctrA [41],
sequence polymorphisms do not permit annealing of these primers and probe [42]. As
expected, the ctrA assay was positive with encapsulated meningococcal isolates and negative
with the six isolates designated as cnl strains using the cnl PCR primers [20]. The 16S rRNA
assay was positive for all Neisseria spp., making it unsuitable for the specific identification of
Nm. Similarly, the crgA primer-probe set recognized N. sicca in addition to Nm and was there-
fore rejected as a meningococcal identification assay reagent. In summary, only the porA assay
was sufficiently specific to identify Nm isolates in the proficiency panel. With the exception of
cnl isolates, the assay targeting ctrA was also suitable for specific identification of Nm.
porA and ctrA grouping of carriage strains by real-time PCR
After establishing that only the porA and ctrA probes were specific for Nm, they were tested
using the Nm carriage isolate collection (n = 234). The porA real time assay was positive for all
isolates. Using the ctrA rt-PCR assay, 193 of 234 isolates (82.5%) were ctrA positive and 42
were ctrA negative (Table 2 and S2 Table). The role of the ctrA assay in our scheme served two
purposes. First, a ctrA positive result reinforced a positive identification of Nm accomplished
by a porA positive result or acted as the sole Nm identifier in the event an isolate was porA neg-
ative. Secondly, a ctrA negative result was indicative of either sequence polymorphism (eg, as
with N. subflava), or partial or complete deletion of the capsule operon. Although this is rare
for invasive disease isolates, it is not uncommon in carriage isolates [20,43]. We therefore
determined the number of porA positive, ctrA negative isolates that lacked the capsule biosyn-
thesis and transport genes (cnl) among the collection of carriage isolates. Of the 42 isolates that
tested negative for ctrA, 29 were confirmed to be cnl (69%).
Identification of sequences that permit discrimination of NmZ and NmE
Following confirmation that the carriage isolates were meningococci using the porA and ctrA
assays, group specific rt-PCR assays were required for serogroup assignment. While rt-PCR
assays for serogroups A, B, C, W, X and Y are available (primer-probe placement illustrated in
Fig 1), no rt-PCR assays for genogrouping NmE and NmZ have been reported. We first
designed NmE and NmZ assays using sequences from the 5’-end of ctrA (Fig 1), but these
lacked the required specificity. To select NmZ specific sequences we analysed genes within the
capsule biosynthesis locus in this serogroup. The GenBank sequence (AJ744766) of the NmZ
reference strain included 4 genes (cszA, cszB, cszC and cszD) in region A of the cps operon
which were NmZ-specific. An alignment to determine the nucleotide similarity of this region
in the eight NmZ isolates sequenced, revealed a 99% DNA sequence identity to the reference
strain in the region harboring all four NmZ capsule biosynthesis genes (cszA, cszB, cszC, and
cszD). Single nucleotide polymorphisms (SNPs) were identified in each gene, including single
nucleotide deletions or insertions within cszB, cszC, and cszD. Isolate PMB3083 was found to
carry the 845 bp insertion element IS1301 at position 2909 of the cszC gene, which is
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commonly 3825 bp long. Five isolates had a cszA gene sequence identical to the reference and
three isolates had only one nucleotide difference, making it the most conserved gene and a
promising candidate for the design of a serogroup specific primer-probe set. A new primer-
probe set targeting cszA was designed (Table 1, Fig 1) and 80 isolates (12 NmZ and 68 NmE)
were evaluated by rt-PCR. All 12 NmZ isolates were correctly identified with the new primer-
probe combination, while all 68 NmE isolates were PCR negative.
To select NmE specific sequences within the capsule biosynthesis locus we relied on the
work reported by Zhu et al [44] and focused on cseG. We sequenced 853 bp of this gene in 64
out of 68 NmE isolates to design a novel primer-probe set (Table 1, Fig 1). The new NmE
primer-probe combination was then used to evaluate the 80 NmE and NmZ isolates described
above. All 68 NmE isolates were positive and the 12 NmZ isolates yielded negative results. In
addition, the newly designed NmE and NmZ primer-probe combinations were only active
against the respective NmE and NmZmeningococci when tested using a set of Nm strains that
included representatives from each of the eight serogroups of interest. The NmE and NmZ
reagents were also negative when tested against the 38 non-meningococcal isolates.
Capsule grouping of carriage strains by real-time PCR
Initial evaluation of the genogrouping primers and probes with genomic DNA and lysates
from meningococcal strains of the eight serogroups (A, B, C, E, W, X, Y and Z) demonstrated
that they were serogroup-specific. They only identified isolates from the corresponding ser-
ogroup and none from the seven heterologous serogroups (S3 Table).
To genogroup the collection of carriage isolates (n = 234) by rt-PCR, reactions were run in
singleplex format, with each 96-well reaction plate including a no template control and a posi-
tive control. Of the 234 carriage isolates in the collection, 181 isolates yielded positive results
with at least one of the genogrouping assays and 53 isolates yielded negative results with all
eight genogrouping assays (S2 Table). The genogroup distribution of these 181 genogroup pos-
itive Nm carriage isolates was NmB (77), NmC (20), NmE (21), NmW (28), NmX (2), NmY
(27), NmZ (4), and mixed (2) (Table 2). None was positive for NmA. Twelve out of fourteen
isolates with initially mixed results were resolved using the algorithm described in the
Methods.
Of the 53 nongenogroupable (NGG) isolates, 29 (54.7%) were cnl and 37 (69.8%) were ctrA
negative.
Evaluation of the typing scheme in the context of carriage isolates
We comparatively evaluated the rt-PCR grouping results with the porA, ctrA, and fhbp assays.
Every carriage isolate that was genogrouped by rt-PCR was also positive in assays that target
genes coding for the two surface proteins, fHbp and PorA. The concordance between rt-PCR
genogroup assignment and ctrA was lower, as five NmB isolates were ctrA negative (Table 2).
The SASG was also conducted to further assess the accuracy of the assay, although it is well
documented that a large proportion of carriage strains are not groupable by SASG due to the
lack of capsule expression [21]. A total of 67 isolates were serogrouped (S2 Table). The concor-
dance between the molecular assay was compared to the SASG assay and it was determined
that of the 67 isolates successfully grouped by SASG, 61 were grouped identically by rt-PCR
(91% agreement, Table 2). Three of the six dissenting isolates were nongenogroupable by rt-
PCR and three classified to a different group. On the other hand, 167 out of 234 isolates in the
collection were NG by SASG (Table 2). However, 112 of these isolates were genogrouped by
the rt-PCR assays. A breakdown by serogroup and the agreement with rt-PCR is shown in
Table 2. The genogrouping of Nm carriage isolates performed by these rt-PCR assays is clearly
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preferred to SASG not only because it is able to group more isolates but also because of its
throughput, sensitivity, and simplicity.
fHbp Composition and diversity in the carriage isolate collection
The carriage isolates were obtained from adolescents and young adults over a five-year period
(1997–2001) that encompassed the introduction of NmC vaccines in the United Kingdom. The
gene that encodes fHbp was detected in all 234 isolates. As has been reported in other Nm car-
riage collections [45,46], the majority of the isolates typed to fHbp subfamily A (185 or 79%).
Fourteen fHbp variants, each identified in three or more isolates, together represented 88% of
the isolates in the study (Fig 2). In this collection, a broader diversity of fHbp variant types
were identified for genogroups B, C, E, and Z than for W, X, and Y, which were primarily com-
posed of isolates carrying fHbp subfamily A variants (Fig 3). There were 21 different fHbp vari-
ants distributed among isolates genogrouped as NmB, with the most abundant being variant
A22 (n = 22). NmW isolates were more homogeneous and predominantly A19 (n = 26). The
distribution of variant B09 spanned genogroups B, E and NG, but was primarily found in iso-
lates genogrouped as E (n = 14).
Discussion
Reliable, sensitive and high-throughput assays allowing the identification and characterization
of Nm isolates are necessary to study the impact of vaccination campaigns on meningococcal
carriage. Here, we describe the development and evaluation of rt-PCR assays for both the
detection and genogroup assignment for Nm.
Fig 2. Diversity of the fHbp variants in the carriage isolate collection.Distribution of fHbp variants found in three or more isolates. Fourteen fHbp variants
encompassed 206 (88%) isolates in the collection. Blue bars, fHbp subfamily A variants; red bars, fHbp subfamily B variants.
doi:10.1371/journal.pone.0132140.g002
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Conventional PCR has been described as a successful approach by several groups for the
identification of Nm disease-causing strains [25,27,44,47,48]. Typing of carriage isolates is con-
siderably more complex. Nm is naturally competent and undergoes rapid genetic changes [49].
While the human pharynx is the reservoir for Nm, disease isolates from within geographic
regions tend to be from a limited range of clonal complexes [30]. The majority of carriage
strains do not express capsule due to either phase variation [50] or the lack of an intact capsule
locus [20]. Although unencapsulated strains of Nm are not generally associated with invasive
disease, in rare instances cnl strains have been isolated from subjects with meningococcal dis-
ease [51]. Assays are based around invasive isolates and though it is assumed that the same
approaches will work in carriage, neither approaches tested here were able to work for all iso-
lates, even in the presence of ctrA, most likely due to small genetic changes. Strains are geneti-
cally competent so even seemingly harmless capsule-deficient strains can recombine to become
virulent [52]; therefore, a vaccine that targets protein antigens may have utility in preventing
the spread of these harmless isolates, too.
Clinical identification of Nm by rt-PCR has been accomplished by targeting various
sequences, including 16S rRNA, insertion elements, crgA, ctrA, porA, and most recently sodC
[29]. Although the sodC assay has been shown to be very robust for detection of Nm, it was not
evaluated here because it was published after this study had been completed. Our evaluation
indicated that rt-PCR assays based on porA and ctrA are specific and accurate enough to iden-
tify Nm among other oropharyngeal associated bacteria. Meningococcal identification based
on conserved regions of porA has been described before by Whiley [31] and Jordens [28] who
both developed porA rt-PCR assays. Some reports described NmB and NmC strains lacking
the porA gene [53–55], but this appears to be uncommon. Harrison et al. [55] reported that
about 13% of the invasive NmC strains in their study had the porA gene deleted. We
Fig 3. Distribution of the fHbp variants by genogroup in the carriage isolate collection.Carriage isolates were categorized by fHbp variant within each
genogroup and are shown according to number of isolates identified. Blue bars, fHbp subfamily A variants; red bars, fHbp subfamily B variants. NGG,
nongenogroupable by rt-PCR.
doi:10.1371/journal.pone.0132140.g003
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hypothesized that by including a redundant assay such as one targeting ctrA, the number of
false negative results produced by porAminus isolates could be reduced. However, the porA
assay by itself appears to be robust for identifying Nm, judged by the positive results in all 234
meningococcal carriage isolates tested. In contrast, the assay targeting ctrA returned negative
results in 42 strains, of which 29 were found to lack all the capsule biosynthesis and transport
genes (cnl), which was in agreement with previous observations [20,21]. In our panel, 69% of
the ctrA negative isolates were also cnl and only 11.9% (5/42) carried at least a portion of the
capsule locus since they were classified as NmB (rt-PCR positive at csb). The negative ctrA
results observed in the other eight isolates (classified as NGG) may be caused by other rear-
rangement events [21]. Although we specifically designed the ctrA assay to target a conserved
region of the gene, we cannot exclude the possibility that sequence polymorphisms resulted in
some ctrA-containing strains being identified as ctrA-negative in our assay. For instance, in
2010, two laboratories independently reported invasive Nm strains harboring ctrA variants
that were missed by the ctrA rt-PCR assay routinely used as a confirmatory test in hospital set-
tings [32,33]; our ctrA primers and probe were specifically designed to capture these novel ctrA
variants, if present.
All 234 isolates in the testing panel carried the gene encoding the outer membrane lipopro-
tein fHbp, which is the antigen in the NmB vaccine Trumenba and one of the component anti-
gens in Bexsero. Although Trumenba is made up of lipidated fHbp variants A05 and B01,
immune sera have bactericidal activity against strains expressing heterologous variants in non-
clinical [13] and Phase 1/2 clinical studies [56]. Sequence typing of the carriage isolates classi-
fied fHbp mostly to subfamily A (185 isolates). Counting of fHbp variants found in three or
more isolates resulted in 14 different variants that together make up 88% of the panel of 234 iso-
lates. Although fhbp was present in isolates from all eight serogroups, we predict that its inher-
ent nucleotide sequence diversity will prevent the design of a universal diagnostic rt-PCR assay.
Also, in this study we developed rt-PCR assays with the goal of identifying up to eight (A, B,
C, E, W, X, Y, and Z) distinct Nm capsular polysaccharide groups. Nucleotide sequences
encoding capsule biosynthesis genes from serogroups A, B, C, W, X and Y, unlike E and Z,
were readily available in GenBank. Evaluation of the testing panel with initial primers-probe
sets that genogroup NmE and NmZ, based on the ctrA gene, revealed random cross-reactivity
with isolates of other serogroups. Because of this observation and the likelihood of missing pro-
spective ctrA negative isolates, they were discontinued. The choice of ctrA as a gene for group-
ing NmE and NmZ described by others [40,48] was prompted by the limited availability of
sequences encoding their capsule biosynthesis genes, a hurdle to confidently design primer-
probes targeting these genes. To further optimize these two assays, we sequenced the capsule
loci of NmE and NmZ strains and designed specific primers and probes based on capsule bio-
synthesis genes unique to each serogroup (cseG and cszA, respectively). We sequenced cseG in
64 NmE isolates to get consensus regions for primer design. The cszA gene was selected based
on the results from sequencing region A of the cps locus in eight NmZ isolates. One of these
harbored the insertion element IS1301 within cszC. Our redesigned primers and probes target-
ing the capsular biosynthesis genes increased the specificity of the genogrouping assays for ser-
ogroups E and Z. An alignment of our cszA rt-PCR amplicon with the cshA gene in the
serogroup H strain previously reported [35] found 100% homology to the probe and one mis-
match in each of the forward and reverse primers. However, lack of NmH isolates prevented us
from evaluating the cross-reactivity of the NmZ sets with NmH. In the future, a reassessment
of this primer-probe set will be facilitated by the availability of sequence data from additional
NmH isolates.
The eight rt-PCR assays were employed to genogroup a diverse set of 234 meningococcal
carriage isolates. They genogrouped 179 of them, 112 more than grouped by SASG. Among the
Expanded Meningococcal Genogrouping Assay
PLOS ONE | DOI:10.1371/journal.pone.0132140 July 6, 2015 13 / 17
isolates serogrouped by SASG, there was a 91% (61/67) agreement with the rt-PCR method. By
rt-PCR, 77 isolates were classified as NmB, compared with the 41 serogrouped as NmB by
SASG. NmW (28) and NmY (27) were followed by a surprisingly high number of NmE isolates
(21) in comparison to the number of NmC (20), NmZ (4), and NmX (2) isolates. As expected,
no NmA was found among these European isolates.
The combined speciation and capsule genogrouping assays were found to be specific and
accurate in identifying and classifying Nm. PCR methods for genogrouping have inherent limi-
tations. As an illustration, not only do they have a narrow range of tolerance to polymor-
phisms, but they are unable to determine the underlying mechanism behind a nongroupable
(NGG) result. As bacterial whole genome sequence (WGS) methods and analysis pipelines
become more efficient, the basis for these inherent limitations will become increasingly appar-
ent. WGS data will also have utility in characterizing carriage isolates and teaching us more
about genetic exchanges and rearrangements in this complex and dangerous organism. Its
inherent higher resolution could help explain the phenotypic differences observed among iso-
lates. Nonetheless, for fast identification of meningococci and the genogrouping of carriage iso-
lates, the rt-PCR assay is the current method of choice because of its speed, simplicity, and
higher throughput.
In summary, the data presented here show that the rt-PCR assays developed for identifica-
tion and genogrouping of eight Nm serogroups (A, B, C, E, W, X, Y, and Z) are specific and
sensitive and have been implemented for the survey of meningococcal carriage in healthy
subjects.
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